+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia



Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia



Blood 85(2): 500-509



A retrospective study of clinical resistance to methotrexate (MTX) was performed on 29 archival specimens of frozen lymphoblasts obtained from children with acute lymphoblastic leukemia (ALL), including 19 at initial presentation and 10 at first relapse. Blasts were assayed for dihydrofolate reductase and MTX transport by flow cytometry using the fluorescent methotrexate analog, PT430 (Rosowsky et al, J Biol Chem 257:14162, 1982). In contrast to tissue culture cells, patient blasts were often heterogeneous for dihydrofolate reductase content. Of the 19 specimens at initial diagnosis, 7 exhibited dual blast populations, characterized by threefold to 10-fold differences in relative dihydrofolate reductase; the dihydrofolate reductase-overproducing populations comprised 12% to 68% of the total blasts for these specimens. Remission duration intervals for patients exhibiting dual blast populations were notably shorter than for patients expressing a single blast population with lower dihydrofolate reductase ( < or = 9 months v > or = 15 months, respectively), a difference that was statistically significant (P = .045). There was no apparent correlation between expression of increased dihydrofolate reductase at diagnosis and known patient and disease prognostic features (immunophenotype, age, sex, and white blood count). For the relapsed patients, 4 of 10 exhibited dual lymphoblast populations with elevated dihydrofolate reductase. The majority of the patient lymphoblast specimens were entirely competent for MTX transport and, likewise, expressed immunoreactive reduced folate carriers by indirect immunofluorescence staining with specific antiserum to the transporter. Three patients (2 at relapse and 1 at diagnosis) exhibited heterogeneous expression of imparied MTX transport (14% to 73% of blasts). In only 1 of these patients did the majority of the lymphoblasts (73%) show impaired MTX transport and for this specimen, immunoreactive carrier proteins were virtually undetectable. These results suggest that heterogeneous expression of elevated dihydrofolate reductase and impaired MTX transport are important modes of resistance in childhood ALL patients undergoing chemotherapy with MTX and that these parameters may serve as predictive indices of clinical response to MTX.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008596383

Download citation: RISBibTeXText

PMID: 7812005


Related references

Methotrexate infusions in poor prognosis acute lymphoblastic leukemia in children: I. The Norwegian methotrexate study in acute lymphoblastic leukemia in childhood, August 1975-December 1980. Medical and Pediatric Oncology 14(3): 187-188, 1986

Methotrexate infusions in poor prognosis acute lymphoblastic leukemia: II. High-dose methotrexate (HDM) in acute lymphoblastic leukemia in childhood: a pilot study from April 1981. Medical and Pediatric Oncology 14(3): 189-190, 1986

Methotrexate infusions in poor prognosis acute lymphoblastic leukemia ii high dose methotrexate in acute lymphoblastic leukemia in childhood a pilot study from april 1981. 1986

Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 86(2): 677-684, 1995

Inhibition of dihydrofolate reductase, methotrexate transport, and growth of methotrexate-sensitive and -resistant L1210 leukemia cells in vitro by 5-substituted 2,4-diaminoquinazolines. Biochemical Pharmacology 34(12): 2163-2167, 1985

Inhibition of dihydrofolate reductase ec 1.5.1.3 and methotrexate transport and the growth of methotrexate sensitive and resistant l 1210 leukemia cells in vitro by 5 substituted 2 4 diaminoquinazolines. Biochemical Pharmacology 34(12): 2163-2168, 1985

Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy. Journal of Pediatric Hematology/Oncology 39(8): 589-595, 2017

Comparison of high dose methotrexate with continuing intrathecal methotrexate versus intrathecal methotrexate alone in low white blood count childhood acute lymphoblastic leukemia Preliminary results from the UKALLXI randomised trial. Blood 92(10 SUPPL 1 PART 1-2): 398A-399A, Nov 15, 1998

Relationship of p15 and p16 gene deletions to elevated dihydrofolate reductase in childhood acute lymphoblastic leukemia. Blood 92(10 SUPPL 1 PART 1-2): 220A-221A, Nov 15, 1998

Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia. Asian Pacific Journal of Cancer Prevention 13(7): 3461-3464, 2013

Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia 16(4): 764-765, 2002

Polymorphisms of methylenetetrahydrofolate reductase and methotrexate sensitivity of childhood B-precursor acute lymphoblastic leukemia. Blood 96(11 Part 1): 100a, November 16, 2000

Dihydrofolate reductase gene amplification in acute lymphoblastic leukemia blasts resistant to methotrexate is associated with mutations in the p53 gene. Blood 82(10 SUPPL 1): 38A, 1993

Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 76(1): 44-49, 1990

High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatric Blood & Cancer 43(1): 17-22, 2004